Vibegron as crushed tablet found safe, efficacious in OAB

The pharmacokinetic drug GEMTESA, developed by Urovant Sciences, was given to adult patients as a single 75-mg dose in a phase 1 study.

FDA updates label for avanafil in men with post-RP erectile dysfunction

The new data are from a randomized, double-blind, parallel, placebo-controlled phase 3 trial that enrolled patients experiencing ED after receiving a bilateral, nerve-sparing radical prostatectomy.

Dr. Lowentritt discusses phase 3 SPOTLIGHT trial on new PSMA-PET tool

"The idea that we may have reliable and consistently interpretable tests for these patients is exciting for the future," says Benjamin Lowentritt, MD, FACS.